Skip to main content

Table 1 Baseline characteristics

From: Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea

  Total (N = 272) Endocrine therapy (N = 137) Chemotherapy (N = 78) Chemotherapy-endocrine therapy (N = 57) p Value
Age, median (range) 39 (16–50) 40 (16–50) 37 (24–49) 39 (18–50) 0.111
ECOG (N = 191) 0.652
 0 88 (46.1%) 43 (47.3%) 22 (38.6%) 23 (53.5%)
 1 100 (52.4%) 47 (51.6%) 34 (59.6%) 19 (44.2%)
 2 3 (1.6%) 1 (1.1%) 1 (1.8%) 1 (2.3%)
Disease status < 0.001
 De novo 89 (32.7%) 25 (18.2%) 28 (35.9%) 36 (63.2%)
 Recurrent 183 (67.3%) 112 (81.8%) 50 (64.1%) 21 (36.8%)
Disease-free interval in recurrent population (n = 176) 0.161
  > 12 months between adjuvant Tx and recurrence 48 (27.3%) 30 (27.3%) 10 (20.8%) 8 (44.4%)
  ≤ 12 months between adjuvant Tx and recurrence 128 (72.7%) 80 (72.7%) 38 (79.2%) 10 (55.6%)
Disease site < 0.001
 Symptomatic visceral 63 (23.2%) 9 (6.6%) 34 (43.6%) 20 (35.1%)
 Asymptomatic visceral 69 (25.4%) 38 (27.7%) 19 (24.4%) 12 (21.1%)
 Bone and soft tissue only 140 (51.4%) 90 (65.7%) 25 (32.1%) 25 (43.9%)
Receptor status 0.010
 ER+ and PgR+ 231 (84.9%) 116 (84.7%) 60 (76.9%) 55 (96.5%)
 ER+ and PgR- 34 (12.5%) 19 (13.9%) 13 (16.7%) 2 (3.5%)
 ER- and PgR+ 7 (2.6%) 2 (1.5%) 5 (6.4%) 0
FSH (N = 178) 0.989
 median (range) 9.14 (0–40) 10.32 (0–39) 9.03 (1–38) 7.39 (2–40)
  1. ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PgR progesterone receptor, Tx treatment. All treatments were begun prior to disease progression